Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study

To evaluate effects of bone marrow sparing (BMS) radiotherapy on decreasing the incidence of acute hematologic toxicity (HT) for locoregionally advanced cervical cancer (LACC) patients treated by pelvic irradiation. LACC patients were recruited prospectively from May 2021 to May 2022 at a single cen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Radiation oncology (London, England) England), 2024-04, Vol.19 (1), p.46-46, Article 46
Hauptverfasser:	Li, Wen, Ma, Lan, Li, Fang, Li, Kemin, Zhang, Yang, Ren, Hongtao, Bao, Xing, Guo, Yuyan, Guo, Ya, Wang, Mincong, Li, Dan, Duan, Yuanqiong, Ma, Xiulong, Wang, Zhongwei, Wang, Yali, Yin, Rutie
Format:	Artikel
Sprache:	eng
Schlagworte:	Biopsy Bladder Blood diseases Body organs Bone marrow Bone Marrow - radiation effects Bone marrow sparing (BMS) Brachytherapy Cancer Cancer therapies Cervical cancer Cervix Chemoradiotherapy - adverse effects Chemotherapy Cisplatin Clinical trials Confidence intervals Drugs Female Health aspects Hematologic toxicity (HT) Humans Irradiation Leukopenia Leukopenia - etiology Lymphatic system Neutropenia Nomograms Patient outcomes Patients Pelvic irradiation Performance prediction Planning Prevention Prospective Studies Radiation Injuries - etiology Radiation therapy Radioisotope brachytherapy Radiotherapy Radiotherapy Dosage Radiotherapy, Intensity-Modulated - methods Regression models Risk factors Statistical analysis Tomography Toxicity Uterine Cervical Neoplasms - radiotherapy Vagina Weekly
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To evaluate effects of bone marrow sparing (BMS) radiotherapy on decreasing the incidence of acute hematologic toxicity (HT) for locoregionally advanced cervical cancer (LACC) patients treated by pelvic irradiation. LACC patients were recruited prospectively from May 2021 to May 2022 at a single center and were evenly randomized into the BMS group and the control group. All patients received pelvic irradiation with concurrent cisplatin (40 mg/m2 weekly), followed by brachytherapy and BM V40
ISSN:	1748-717X 1748-717X
DOI:	10.1186/s13014-024-02432-7